Liquidia Corporation Common Stock vs Mizuho Financial Group Inc. Sponosred ADR (Japan) — how do they compare? Liquidia Corporation Common Stock trades at $33.75 (market cap $3.04B), while Mizuho Financial Group Inc. Sponosred ADR (Japan) trades at $10.09 (market cap $124.07B). The key difference: Mizuho Financial Group Inc. Sponosred ADR (Japan) is far larger — about 40.8× Liquidia Corporation Common Stock's market cap, and Mizuho Financial Group Inc. Sponosred ADR (Japan) pays a 1.79% dividend while Liquidia Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Mizuho Financial Group Inc. Sponosred ADR (Japan) for 6 Days on average.
| LQDA | MFG | |
|---|---|---|
Market Cap | $3.04B | $124.07B |
Volume | 21,111,778 | 3,230,414 |
Sector | Health | Financials |
52-Week High | $91.03 | $11.45 |
52-Week Low | $22.02 | $6.23 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.94B | $34.39T |
Dividend Yield | — | 1.79% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Mizuho Financial Group (MFG) trades at $10.60, up slightly by 0.09% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.22 exceeding the $0.17 estimate. Revenue grew to $3.65T in 2025, with a net income margin of 30.42% and a P/E ratio of 14.96, indicating reasonable valuation. Recent news highlights institutional stake adjustments and positive CRA ratings.
MFG presents a mixed outlook; earnings momentum and solid profitability support upside, but bearish technicals and analyst caution (60% hold rating) suggest near-term pressure. Key risks include declining cash flow trends and rising debt-to-asset ratio, while institutional interest and dividend growth potential offer opportunities for long-term investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →Mizuho Financial Group is a Japanese financial services company offering banking, trust, securities, and asset management services. It serves retail, corporate, and institutional clients globally.
Read more on MFG →